Immunological engineering Flashcards

1
Q

What are the antibody characteristics of CVID?

A

Low IgG, low IgA and/or low IgM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the antibody characteristics of a IgG subclass deficiency?

A

Normal total IgG, low subclass of IgG1-4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the antibody characteristics of selective antibody deficiency with normal immunoglobulin?

A

Normal total IgG + normal subclasses, disturbed response to immunization with T-cell independent polysaccharide antigens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are current treatment options for antibody deficiencies? (4)

A
  1. Antibiotic treatment upon infection or phopylactic
  2. Immunoglobulin replacement therapy IVIG/SCIg
  3. Immunomodulatory treatment (when paired with auto-immunological symptoms)
  4. HSCT (in case of SCID)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How many % of PID patients have a primary antibody deficiency?

A

66%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which type of primary immunodeficiency is most common?

A

Antibody deficiencies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the advantage of monogenic primary immunodeficiencies?

A

Could allow for targeting of affected gene/protein with small molecule inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Most primary immunodeficiencies are [monogenetic/polygenetic]

A

Polygenetic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are reasons for genetic testing in patients with antibody deficiencies? (4)

A
  1. Counselling
  2. Better understanding of disease & mechanisms
  3. Prediction of prognosis & complications
  4. Could offer therapeutic options
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which strategies are available for genetic testing?

A
  1. Single gene Sanger sequencing
  2. Gene panel analysis by Sanger/NGS
  3. Whole exome sequencing (WES)/whole genome sequencing (WGS) by NGS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the advantage of single gene Sanger sequencing for genetic testing?

A

Highly accurate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the disadvantages of single gene Sanger sequencing for genetic testing? (3)

A
  1. Expensive
  2. Laborious
  3. Time-consuming
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which kind of mutations can be detected with single gene Sanger sequencing?

A
  1. Point mutations
  2. Intronic mutations
  3. Some deletions/duplications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

In which instances is single gene Sanger sequencing for genetic testing especially useful?

A

When there is one suspected causative gene -> can be sequenced with high accuracy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which method of genetic testing is most commonly used in patients with primary antibody deficiencies?

A

Gene panel analysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How does gene panel analysis work?

A

Screens for well-characterized clinical syndromes & phenotypes that have a high likelihood of belonging to a subset of genetic mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the downside of gene panel analysis?

A

Only focusses on a list of included, well-known genes -> will not find novel mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How many % of the human genome is screened by whole exome sequencing?

A

~1% (only exons of protein-coding genes)

19
Q

What is the advantage of WES/WGS over gene panels?

A

They are able to detect novel mutations

20
Q

How is WES/NGS usually performed?

A

Trio analysis -> parents + child screened

21
Q

Which gene elements are also included in WGS (in addition to WES)? (4)

A
  1. Intronic mutations
  2. Splice site mutations
  3. Regulatory element mutations
  4. Non-exonic mutations
22
Q

What is APDS?

A

Activated PI3Kδ syndrome

23
Q

What is the function of PI3Kδ?

A

Involved in the mTOR pathway -> important for B- and T-cell activation

24
Q

In which processes is PI3Kδ involved?

A
  1. Downstream signalling of the BCR
  2. T- and B-cell development (survival signals)
25
Q

What is the prevalence of APDS?

A

1-2/million

26
Q

What causes APDS?

A

Mutations encoding the subunits of the PI3Kδ complex

27
Q

What is the result PI3Kδ mutations in APDS?

A

Continuous activity of PI3Kδ, leading to increased numbers of immature & senescent B-cells and T-cells (and a decreased number of healthy cells)

28
Q

What are the clinical features of APDS?

A
  1. Low levels of antibodies
  2. Recurrent infections
  3. Auto-immune disease
  4. Increased risk of lymphoproliferation & haematological malignancies
29
Q

What are pathogens frequently seen as infections in APDS patients? (7)

A
  1. Encasulated bacteria
  2. CMV
  3. EBV
  4. VZV
  5. HPV
  6. Adenovirus
  7. Molluscum contagiosum
30
Q

Which infectious diseases are frequently seen in APDS patients? (5) Which is most common?

A
  1. Pneumonia = most common
  2. Consolidations of the lung
  3. Bronchiectasis
  4. Interstitial lung disease
  5. Gastrointestinal infections
31
Q

Which forms of systemic auto-immune disease are frequently seen in APDS patients? (4)

A
  1. Haemolytic anaemia
  2. ITP
  3. Neutropenia
  4. Evans syndrome
32
Q

Which forms of local auto-immune disease are frequently seen in APDS patients? (2)

A
  1. Gastro-intestinal
  2. Liver disease
33
Q

Which forms of non-malignant lymphoproliferative diseases are frequently seen in APDS? (3)

A
  1. Lymphadenopathy
  2. Hepatosplenomegaly
  3. Nodular lympohid hyperplasia of airway & GI-mucosa
34
Q

Which forms of malignant haematological diseases are frequently seen in APDS? (4)

A
  1. Diffuse large-cell B-cell lymphoma (DLBCL)
  2. Hodgkin’s lymphoma
  3. Marginal zone B-cell lymphoma
  4. MALToma
35
Q

How can APDS be pharmacologically targeted?

A

Inhibiting the PI3Kδ complex

36
Q

Which drug is available for APDS?

A

Leniolisib

37
Q

What is the risk of PI3Kδ inhibition?

A

Decreased capacity of immune activation

38
Q

What is the effect of ideal dosing of leniolisib?

A

Activity of the PI3Kδ inhibited in such a way that it is decreased to physiological levels

39
Q

What are the effects of leniolisib (compared to placebo) in APDS? (5)

A
  1. Changes in B-cell subsets: more naïve B-cells, less transitional B-cells, decrease in plasmablasts
  2. Decrease in serum IgM
  3. Decrease in senescent cells as part of total T-cells
  4. Decrease in lymphadenopathy
  5. Increased patient-well being
40
Q

What is reduced lymphadenopathy of ADPS patients receiving leniolisib correlated with?

A

Decrease in haematological malignancy

41
Q

True or false: leniolisib has side effects on the gastro-intestinal tract

A

False; leniolisib has very little side effects (if properly dosed)

42
Q

What are the long-term effects of leniolisib use in APDS patients? (6)

A
  1. Mild increase in health-related quality over time
  2. 37% decrease in immunoglobulin replacement therapy over time, with some patients fully IRT-independent
  3. Decreased infection rate
  4. Long-term reduction of lymphadenopathy
  5. Long-term reduction of serum IgM & increase of IgG
  6. Restoration of B- and T-cell subsets to physiological levels
43
Q

What is the downside of small molecule treatment of rare genetic diseases?

A

Treatments often very expensive + needs to be chronically administered